Non Small Cell Lung Cancer - icotinib - EGFR mutation + WNT5A expression

Association details:

Biomarker:	EGFR mutation + WNT5A expression
Cancer:	Non Small Cell Lung Cancer
Drug:	Conmana (icotinib) (EGFR inhibitor)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: D – Preclinical

Source:

IASLC-WCLC 2020

Title:

P35.25 - E2F1-Mediated Repression of WNT5A Expression Promotes Brain Metastasis via the ERK1/2 Pathway in EGFR-Mutant Non-Small Cell Lung Cancer

Published date:

01/12/2021

Excerpt:

The expression levels of WNT5A in NSCLC plasma (n=94) and cells were detected by quantitative real-time PCR (qRT-PCR) and western blot analysis....An EGFR-tyrosine kinase inhibitor (TKI), Icotinib, inhibited EGFR-mutant signaling pathways, significantly attenuating the inhibition of WNT5A expression….Our research revealed the role of WNT5A in NSCLC BM with EGFR mutation and proved that E2F1-mediated repression of WNT5A was dependent on the ERK1/2 pathway...